Oncogenic chromosomal translocations and human cancer (Review)

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2011-2019

  Zheng, Jie ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Cancer; Chromosomal translocation; Effect; Fusion protein; Gene positioning

Indexed keywords

HYBRID PROTEIN; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BURKITT LYMPHOMA; CELL NUCLEUS; CHROMATIN; CHROMOSOME 14; CHROMOSOME 15; CHROMOSOME 17; CHROMOSOME 18; CHROMOSOME TRANSLOCATION; DNA REPAIR; EWING SARCOMA; GENE ACTIVATION; GENE LOCUS; GENOME; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR MECHANICS; NEOPLASM; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; PROSTATE CARCINOMA; REVIEW;

CELL NUCLEUS; CHROMATIN; GENOME, HUMAN; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 84885058672     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2677     Document Type: Review

References (105)

1. Mitelman F, Johansson B and Mertens F: The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7: 233-245, 2007.
2. Nambiar M, Kari V and Raghavan SC: Chromosomal translocations in cancer. Biochim Biophys Acta 1786: 139-152, 2008.
3. Fröhling S and Döhner H: Chromosomal abnormalities in cancer. N Engl J Med 359: 722-734, 2008.
4. Pui CH, Relling MV and Downing JR: Acute lymphoblastic leukemia. N Engl J Med 350: 1535-1548, 2004.
5. Aplan PD: Causes of oncogenic chromosomal translocation. Trends Genet 22: 46-55, 2006.
6. Raghavan SC and Lieber MR: DNA structures at chromosomal translocation sites. Bioessays 28: 480-494, 2006.
7. Hakim O, Resch W, Yamane A, et al: DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes. Nature 484: 69-74, 2012.
8. Meaburn KJ, Misteli T and Soutoglou E: Spatial genome organization in the formation of chromosomal translocations. Semin Cancer Biol 17: 80-90, 2007.
9. Kozubek S, Lukásová E, Marecková A, et al: The topological organization of chromosomes 9 and 22 in cell nuclei has a determinative role in the induction of t(9,22) translocations and in the pathogenesis of t(9,22) leukemias. Chromosoma 108: 426-435, 1999.
10. Neves H, Ramos C, da Silva MG, Parreira A and Parreira L: The nuclear topography of ABL, BCR, PML, and RARα genes: evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation. Blood 93: 1197-1207, 1999.
11. Collins SJ: Retinoic acid receptors, hematopoiesis and leukemogenesis. Curr Opin Hematol 15: 346-351, 2008.
12. Roix JJ, McQueen PG, Munson PJ, Parada LA and Misteli T: Spatial proximity of translocation-prone gene loci in human lymphomas. Nat Genet 34: 287-291, 2003.
13. Misteli T: The inner life of the genome. Sci Am 304: 66-73, 2011.
14. Osborne CS, Chakalova L, Mitchell JA, et al: Myc dynamically and preferentially relocates to a transcription factory occupied by Igh. PLoS Biol 5: e192, 2007.
15. Cornfield DB, Mitchell DM, Almasri NM, Anderson JB, Ahrens KP, Dooley EO and Braylan RC: Follicular lymphoma can be distinguished from benign follicular hyperplasia by flow cytometry using simultaneous staining of cytoplasmic bcl-2 and cell surface CD20. Am J Clin Pathol 114: 258-263, 2000.
16. Welzel N, Le T, Marculescu R, et al: Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res 61: 1629-1636, 2001.
17. Palmer RH, Vernersson E, Grabbe C and Hallberg B: Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420: 345-361, 2009.
18. Barreca A, Lasorsa E, Riera L, et al: Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 47: R11-R23, 2011.
19. Iwahara T, Fujimoto J, Wen D, et al: Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14: 439-449, 1997.
20. Mathas S, Kreher S, Meaburn KJ, et al: Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proc Natl Acad Sci USA 106: 5831-5836, 2009.
21. Gandhi M, Evdokimova V and Nikiforov YE: Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma. Mol Cell Endocrinol 321: 36-43, 2010.
22. Merolla F, Pentimalli F, Pacelli R, Vecchio G, Fusco A, Grieco M and Celetti A: Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage. Oncogene 26: 6167-6175, 2007.
23. Nikiforov YE: Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21 (Suppl 2): S37-S43, 2008.
24. Ciampi R, Giordano TJ, Wikenheiser-Brokamp K, Koenig RJ and Nikiforov YE: HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocr Relat Cancer 14: 445-452, 2007.
25. Gandhi M, Medvedovic M, Stringer JR and Nikiforov YE: Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements. Oncogene 25: 2360-2366, 2006.
26. Clark J, Merson S, Jhavar S, et al: Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26: 2667-2673, 2007.
27. Lin C, Yang L, Tanasa B, et al: Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139: 1069-1083, 2009.
28. Squire JA, Park PC, Yoshimoto M, Alami J, Williams JL, Evans A and Joshua AM: Prostate cancer as a model system for genetic diversity in tumors. Adv Cancer Res 112: 183-216, 2011.
29. Kumar-Sinha C, Tomlins SA and Chinnaiyan AM: Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8: 497-511, 2008.
30. Seth A and Watson DK: ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41: 2462-2478, 2005.
31. Sankar S and Lessnick SL: Promiscuous partnerships in Ewing's sarcoma. Cancer Genet 204: 351-365, 2011.
32. Patel M, Simon JM, Iglesia MD, Wu SB, McFadden AW, Lieb JD and Davis IJ: Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. Genome Res 22: 259-270, 2012.
33. Zelent A, Greaves M and Enver T: Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 23: 4275-4283, 2004.
34. Bohlander SK: ETV6: a versatile player in leukemogenesis. Semin Cancer Biol 15: 162-174, 2005.
35. Li Z, Tognon CE, Godinho FJ, et al: ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell 12: 542-558, 2007.
36. Vaarala MH, Porvari K, Kyllönen A, Lukkarinen O and Vihko P: The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer 94: 705-710, 2001.
37. Mani RS, Tomlins SA, Callahan K, et al: Induced chromosomal proximity and gene fusions in prostate cancer. Science 326: 1230, 2009.
38. Bastus NC, Boyd LK, Mao X, et al: Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 70: 9544-9548, 2010.
39. Hu Q, Kwon YS, Nunez E, et al: Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules. Proc Natl Acad Sci USA 105: 19199-19204, 2008.
40. Soutoglou E, Dorn JF, Sengupta K, et al: Positional stability of single double-strand breaks in mammalian cells. Nat Cell Biol 9: 675-682, 2007.
41. Parada LA, McQueen PG and Misteli T: Tissue-specific spatial organization of genomes. Genome Biol 5: R44, 2004.
42. Ortiz de Mendíbil I, Vizmanos JL and Novo FJ: Signatures of selection in fusion transcripts resulting from chromosomal translocations in human cancer. PLoS One 4: e4805, 2009.
43. Bickmore WA and Teague P: Influences of chromosome size, gene density and nuclear position on the frequency of constitutional translocations in the human population. Chromosome Res 10: 707-715, 2002.
44. Narsing S, Jelsovsky Z, Mbah A and Blanck G: Genes that contribute to cancer fusion genes are large and evolutionarily conserved. Cancer Genet Cytogenet 191: 78-84, 2009.
45. Burrow AA, Williams LE, Pierce LC and Wang YH: Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites. BMC Genomics 10: 59, 2009.
46. Branco MR and Pombo A: Intermingling of chromosome territories in interphase suggests role in translocations and transcription-dependent associations. PLoS Biol 4: e138, 2006.
47. Chiarle R, Zhang Y, Frock RL, et al: Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell 147: 107-119, 2011.
48. Obe G, Pfeiffer P, Savage JR, et al: Chromosomal aberrations: formation, identification and distribution. Mutat Res 504: 17-36, 2002.
49. Cowell IG, Sunter NJ, Singh PB, Austin CA, Durkacz BW and Tilby MJ: γH2AX foci form preferentially in euchromatin after ionising-radiation. PLoS One 2: e1057, 2007.
50. Lorat Y, Schanz S, Schuler N, Wennemuth G, Rübe C and Rübe CE: Beyond repair foci: DNA double-strand break repair in euchromatic and heterochromatic compartments analyzed by transmission electron microscopy. PLoS One 7: e38165, 2012.
51. Murray JM, Stiff T and Jeggo PA: DNA double-strand break repair within heterochromatic regions. Biochem Soc Trans 40: 173-178, 2012.
52. Turc-Carel C, Aurias A, Mugneret F, et al: Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 32: 229-238, 1988.
53. Wang J, Cai Y, Ren C and Ittmann M: Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66: 8347-8351, 2006.
54. Wang J, Cai Y, Shao LJ, et al: Activation of NF-κB by TMPRSS2/ERG fusion isoforms through toll-like receptor-4. Cancer Res 71: 1325-1333, 2011.
55. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA and Schalken JA: ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 56: 275-286, 2009.
56. Yuan Y, Zhou L, Miyamoto T, et al: AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 98: 10398-10403, 2001.
57. Licht JD and Sternberg DW: The molecular pathology of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2005: 137-142, 2005.
58. Rubnitz JE, Raimondi SC, Halbert AR, et al: Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience. Leukemia 16: 2072-2077, 2002.
59. Okumura AJ, Peterson LF, Okumura F, Boyapati A and Zhang DE: t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression. Blood 112: 1392-1401, 2008.
60. Wang J, Wang M and Liu JM: Domains involved in ETO and human N-CoR interaction and ETO transcription repression. Leuk Res 28: 409-414, 2004.
61. Wang L and Hiebert SW: TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3. Oncogene 20: 3716-3725, 2001.
62. Mengeling BJ, Phan TQ, Goodson ML and Privalsky ML: Aberrant corepressor interactions implicated in PML-RARα and PLZF-RARα leukemogenesis reflect an altered recruitment and release of specific NCoR and SMRT splice variants. J Biol Chem 286: 4236-4247, 2011.
63. Zhang XW, Yan XJ, Zhou ZR, et al: Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science 328: 240-243, 2010.
64. Mueller D, García-Cuéllar MP, Bach C, Buhl S, Maethner E and Slany RK: Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol 7: e1000249, 2009.
65. Balgobind BV, Zwaan CM, Pieters R and Van den Heuvel-Eibrink MM: The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia 25: 1239-1248, 2011.
66. Liu H, Cheng EH and Hsieh JJ: MLL fusions: pathways to leukemia. Cancer Biol Ther 8: 1204-1211, 2009.
67. Krivtsov AV and Armstrong SA: MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7: 823-833, 2007.
68. Dobson CL, Warren AJ, Pannell R, Forster A and Rabbitts TH: Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene. EMBO J 19: 843-851, 2000.
69. Bernt KM, Zhu N, Sinha AU, et al: MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20: 66-78, 2011.
70. Daigle SR, Olhava EJ, Therkelsen CA, et al: Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20: 53-65, 2011.
71. Liu H, Cheng EH and Hsieh JJ: Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev 21: 2385-2398, 2007.
72. Ayton PM and Cleary ML: Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17: 2298-2307, 2003.
73. Zeisig BB, Schreiner S, García-Cuéllar MP and Slany RK: Transcriptional activation is a key function encoded by MLL fusion partners. Leukemia 17: 359-365, 2003.
74. Okada Y, Feng Q, Lin Y, et al: hDOT1L links histone methylation to leukemogenesis. Cell 121: 167-178, 2005.
75. Wong P, Iwasaki M, Somervaille TC, So CW and Cleary ML: Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev 21: 2762-2774, 2007.
76. So CW, Lin M, Ayton PM, Chen EH and Cleary ML: Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 4: 99-110, 2003.
77. So CW and Cleary ML: Dimerization: a versatile switch for oncogenesis. Blood 104: 919-922, 2004.
78. Bischof D, Pulford K, Mason DY and Morris SW: Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 17: 2312-2325, 1997.
79. Goldman JM and Melo JV: Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 349: 1451-1464, 2003.
80. Ladanyi M and Cavalchire G: Molecular variant of the NPM-ALK rearrangement of Ki-1 lymphoma involving a cryptic ALK splice site. Genes Chromosomes Cancer 15: 173-177, 1996.
81. Jhiang SM: The RET proto-oncogene in human cancers. Oncogene 19: 5590-5597, 2000.
82. Zhao X, Ghaffari S, Lodish H, Malashkevich VN and Kim PS: Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol 9: 117-120, 2002.
83. Alberti L, Carniti C, Miranda C, Roccato E and Pierotti MA: RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol 195: 168-186, 2003.
84. Mizuki M, Ueda S, Matsumura I, Ishiko J, Schwäble J, Serve H and Kanakura Y: Oncogenic receptor tyrosine kinase in leukemia. Cell Mol Biol 49: 907-922, 2003.
85. Mano H: Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 99: 2349-2355, 2008.
86. Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, Superti-Furga G and Kuriyan J: Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell 21: 787-798, 2006.
87. Chen S, Dumitrescu TP, Smithgall TE and Engen JR: Abl N-terminal cap stabilization of SH3 domain dynamics. Biochemistry 47: 5795-5803, 2008.
88. Mian AA, Oancea C, Zhao Z, Ottmann OG and Ruthardt M: Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia 23: 2242-2247, 2009.
89. He Y, Wertheim JA, Xu L, Miller JP, Karnell FG and Choi JK: The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood 99: 2957-2968, 2002.
90. Reddy EP and Aggarwal AK: The ins and outs of bcr-abl inhibition. Genes Cancer 3: 447-454, 2012.
91. Tong Q, Xing S and Jhiang SM: Leucine zipper-mediated dimerization is essential for the PTC1 oncogenic activity. J Biol Chem 272: 9043-9047, 1997.
92. Pillai RN and Ramalingam SS: The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation. Curr Oncol Rep 14: 105-110, 2012.
93. Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12: 1004-1012, 2011.
94. Willis TG and Dyer MJ: The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 96: 808-822, 2000.
95. Dadi S, Le Noir S, Asnafi V, Beldjord K and Macintyre EA: Normal and pathological V(D)J recombination: contribution to the understanding of human lymphoid malignancies. Adv Exp Med Biol 650: 180-194, 2009.
96. Martinez-Climent JA, Fontan L, Gascoyne RD, Siebert R and Prosper F: Lymphoma stem cells: enough evidence to support their existence? Haematologica 95: 293-302, 2010.
97. Graux C, Cools J, Michaux L, Vandenberghe P and Hagemeijer A: Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia 20: 1496-1510, 2006.
98. Van Vlierberghe P, van Grotel M, Beverloo HB, et al: The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood 108: 3520-3529, 2006.
99. Brake RL, Kees UR and Watt PM: Multiple negative elements contribute to repression of the HOX11 proto-oncogene. Oncogene 17: 1787-1795, 1998.
100. Riz I, Hawley TS, Johnston H and Hawley RG: Role of TLX1 in T-cell acute lymphoblastic leukaemia pathogenesis. Br J Haematol 145: 140-143, 2009.
101. Kees UR, Heerema NA, Kumar R, et al: Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children's Cancer Group (CCG). Leukemia 17: 887-893, 2003.
102. Dadi S, Le Noir S, Payet-Bornet D, et al: TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRα gene expression. Cancer Cell 21: 563-576, 2012.
103. De Keersmaecker K, Marynen P and Cools J: Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica 90: 1116-1127, 2005.
104. Grabher C, von Boehmer H and Look AT: Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 6: 347-359, 2006.
105. South AP, Cho RJ and Aster JC: The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol 23: 458-464, 2012.